Haleon and Halozyme report corporate financial activities

Haleon plc has announced the results and pricing terms of a cash tender offer for its outstanding 3.375% Fixed Rate Senior Notes due March 2027. The offer, made through its subsidiary Haleon US Capital LLC, involves approximately $1.34 billion in tendered principal amount out of the total $1.999 billion outstanding. The notes are fully and unconditionally guaranteed by Haleon.

Separately, Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of company stock on August 18. The transaction, executed under a pre-arranged Rule 10b5-1 trading plan, had an average price of $104.18, totaling approximately $2.08 million. Following the sale, Torley retains direct ownership of 767,780 shares.